vaccine

50,000 frontline staff to receive a jab for a different Ebola strain, with 20,000 enrolled in a one-year clinical trial.

Health workers in parts of the Democratic Republic of the Congo (DRC) have begun to receive a vaccine that many hope will provide a level of protection against the Ebola virus.

The vaccine rollout started on Saturday in Bunia, the capital of Ituri province in the northeastern DRC. Ituri is the epicentre of the fastest-growing outbreak of Ebola in history.

The provincial governor, Major-General Gaby Kasongo Mulumba, said health workers there “are particularly exposed and deeply involved in the response”.

The operation, backed by the World Health Organization and Doctors Without Borders, known by its French initials MSF, will also target North Kivu, where cases have been rising sharply, health authorities said.

Some 50,000 health and other frontline workers will be injected with the Ervebo vaccine, which was developed for use against the more common Zaire strain.

Its effectiveness against the current Ebola strain caused by the Bundibugyo virus will be monitored in 20,000 recipients for up to one year.

Clinical trials are ongoing to find a licensed vaccine for the latest outbreak, which has no licensed vaccine or proven treatment.

“We don’t know to what degree it might be effective against the Bundibugyo strain,” Steve Ahuka, a Congolese official who is part of the health task force against the Ebola outbreak, said.

Dr Jeannot Elua said at a health facility in Bunia the vaccine was “beneficial”.

“We healthcare workers don’t really have a choice. We are going to receive it,” he told the Associated Press news agency. “Some people here had already received the previous vaccine. I received it myself, because it was mandatory.”

WHO experts have said that early data on the Ervebo vaccine, notably from animal trials, suggested it could offer some protection in the current outbreak.

The virus has killed at least 3,639 and infected some 7,541 people since May. Some 1,823 people have recovered, according to the latest figures from local authorities.

The WHO said in August that 70,000 doses of Ervebo were approved for use in the DRC.

The vaccine is being used under a compassionate-use programme, which allows a medical product to be used in a serious disease situation even though it has not been specifically approved for that particular use.

While WHO officials have cited “encouraging signs” that transmission may be slowing, MSF warned on Friday that there is no clear evidence the epidemic is coming under control.

Sept. 2 (UPI) — A group of medical organizations has released guidance on fall vaccinations against respiratory illnesses.

The Centers for Disease Control and Prevention usually launches a fall campaign to recommend seasonal vaccines for diseases like RSV, influenza and COVID-19. This year, however, the agency has not issued its updated recommendations for the respiratory virus season.

In March, the American Academy of Pediatrics won a lawsuit against the federal government that blocked Health and Human Services Secretary Robert F. Kennedy Jr. from overhauling the childhood vaccine schedule.

Kennedy and President Donald Trump have said that children get too many vaccines and have reduced the number of vaccines routinely recommended. They have also linked vaccines to autism, which has been proven untrue by research.

In response, the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, the American Academy of Family Physicians, the Infectious Diseases Society of America each issued guidelines for fall immunizations. They based those guidelines on research from the American Medical Association and the University of Minnesota’s Vaccine Integrity Project

Last year, the CDC changed the COVID-19 recommendations to say that patients should talk to their own doctors.

On Tuesday, the agency said, “the CDC states the recommendations for seasonal influenza vaccination from the July 2025 immunization schedule remain in effect for the 2026-2027 influenza season.” It doesn’t mention the new mRNA flu vaccine, approved by the U.S. Food and Drug Administration last month.

“For more than 60 years, the United States has benefited from an established federal process for evaluating vaccine evidence and translating that science into recommendations for the American public. At the center of that process were the Centers for Disease Control and its Advisory Committee on Immunization Practices, the ACIP,” CNN reported Dr. Bruce Gellin, board chair of the Vaccine Integrity Project and professor of medicine at Georgetown University, said at a press briefing.

“Unfortunately today, the federal government is not fulfilling that responsibility in the way that it historically has. But the need for that work has not disappeared. Influenza, SARS-CoV-2 [COVID-19] and the RSV viruses will circulate again this fall and winter,” Gellin said.

“We cannot allow the breakdown of a federal process to create a vacuum in evidence-based vaccine guidance,” he added.

Dr. Sarah Nosal, president of the American Academy of Family Physicians, said in the news briefing that insurance companies have indicated they will cover the vaccines.

“Vaccines are one of medicine’s greatest success stories. They prevent serious illness, reduce hospitalizations and long-term complications and save lives,” Nosal said in a press release. “As federal guidance evolves, the science behind vaccines remains strong. These recommendations are grounded in the latest evidence, informed by public health experts and shaped by what family physicians are seeing every day in their patients.”

The doses are the first of 70,000 allocated for Kinshasa as experts warn of the virus’s exponential spread.

The Democratic Republic of the Congo (DRC) has received more than 16,000 doses of the Ervebo vaccine as the country faces its deadliest-ever Ebola outbreak.

The 16,250 doses arrived in the capital, Kinshasa, late on Friday evening, comprising the first of 70,000 that the World Health Organization (WHO) and partners pledged to provide on Thursday.

More doses are set to arrive next week.

Although the vaccine is approved against the Zaire strain of the virus, the Bundibugyo strain currently circulating in the country has no approved vaccine or treatment.

Early data from animal trials show it may offer some protection, according to the WHO.

Samuel Roger Kamba, the DRC’s health minister, told reporters Ervebo had been used several times in the past, including “on a very large scale” during the 2018 to 2020 outbreak.

Of the 70,000 doses intended for the DRC, 20,000 will be part of a late-stage clinical trial to test its effect on the Bundibugyo strain, the WHO said. The remainder is allocated to front-line and health workers.

The outbreak has killed more than 2,500 people out of nearly 5,300 confirmed cases, with the United Nations warning this week that infections continue to spread “exponentially”.

Although the outbreak was declared in mid-May, it is believed to have started weeks beforehand. Data from the Africa Centres for Disease Control and Prevention, meanwhile, shows that transmission has not yet peaked and could reach three times its known rate.

Efforts to contain the virus have been stymied by ongoing armed conflict, delays in identifying cases and a lack of infrastructure in eastern DRC, experts say.